Elizabeth Adkins Czerepak brings 18 years of pharmaceutical industry experience and nine years of venture capital experience to Cancer Genetics. Elizabeth co-founded Bear Stearns Health Innoventures (BSHI), a $212 million venture capital fund that led investments in thirteen biotechnology companies, seven of which she served as a board member. Concurrent to BSHI, she held the position of Managing Director of Bear, Stearns & Co., and later JPMorgan, where she was an NASD Registered Representative. Earlier, Elizabeth held senior positions in licensing, business development, and finance at BASF Pharma, Hoffmann-La Roche, and Merck & Co., where she led or supported over 30 licensing and M&A transactions, including Roche’s acquisition of PCR technology from Cetus, and the licensing of the P53 gene from Johns Hopkins University. Elizabeth holds an MBA from Rutgers University and a B.A. magna cum laude from Marshall University and is a member of the Licensing Executives Society.